John C. Wain

Brigham and Women's Hospital — United States

Medicine · Health Sciences

83h-index24.4kcitations307works0.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tracheal and airway disorders(49), Transplantation: Methods and Outcomes(43), Lung Cancer Diagnosis and Treatment(30), Esophageal and GI Pathology(28), Esophageal Cancer Research and Treatment(24)

Publications307 total

Data from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S6 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Cancer Immunology Research·2025· 6 citedOpen Access
In vivo microscopic imaging for diagnosis of fibrotic interstitial lung disease using endobronchial optical coherence tomography
2021
In vivo microscopic assessment of idiopathic pulmonary fibrosis using endobronchial optical coherence tomography: a prospective diagnostic study
2021
Endobronchial Optical Coherence Tomography for In Vivo Microscopic Diagnosis of Pulmonary Fibrosis
2020· 1 citedOpen Access
In vivo diagnosis of idiopathic pulmonary fibrosis (IPF) using endobronchial OCT (Conference Presentation)
2020· 1 cited
A Decade-Long Ground Glass Opacity of Mystery
2019
Polarization Sensitive Optical Coherence Tomography for In Vivo Microscopic Detection of Pulmonary Fibrosis
2019
page 1 of 16Next →

Frequent Co-authors

Douglas J. Mathisen(27), Cameron D. Wright(22), Hermes C. Grillo(19), David C. Christiani(15), Dean M. Donahue(14), Henning A. Gaissert(12), Thomas J. Lynch(11), Geoffrey Liu(8), John K. Wiencke(7), Karl T. Kelsey(7), Ashby C. Moncure(7), Michael Lanuti(6), Wei Zhou(6), Donna Neuberg(4), Alan D. Hilgenberg(4), David P. Miller(4), Li Su(4), Lecia V. Sequist(3), Subba R. Digumarthy(3), Alice T. Shaw(3)